The U.S Food and Drug Administration (FDA) has approved Biogen’s aducanumab treatment for Alzheimer’s which aims to eliminate the sticky deposits of amyloid beta found in the brains of patients in the initial stages of the disease. In spite of controversy and complicated clinical trial data, the FDA has concluded that Aduhelm, the name in which the drug will be sold under, did reduce specific plaques that can lead to the overall deterioration of the patients. The trial studied patients who tested positive for a component of amyloid brain plaques. Following the approval, the FDA acknowledged that Biogen should carry out a post-approval clinical trial to validate the drug’s clinical effectiveness.
Read more here.